Preclinical data for Cereno Scientific’s drug candidate CS585 showing high selectivity for the IP receptor presented at the EHA 2024 Hybrid Congress
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that an abstract on the preclinical drug candidate, novel IP receptor agonist CS585, was presented at the EHA 2024 Hybrid Congress, in Madrid, June 15th, 2024.The abstract titled “Superior Selectivity of CS585 to The Prostacyclin Receptor Translates to A New Viable Target for Prevention of Thrombosis”, was authored by L. Stanger, P Yalavarthi, A. Rickenberg, K. Goerger, D. Gilmore and M. Holinstat, at University of Michigan, Ann